MedPath

Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting

Phase 3
Completed
Conditions
HIV Infections
Streptococcus Pneumoniae
Interventions
Biological: pneumococcal conjugate vaccine
Biological: pneumococcal polysaccharide vaccine
Registration Number
NCT00622843
Lead Sponsor
Uniformed Services University of the Health Sciences
Brief Summary

Purpose: To study the immune response of the newly licensed pneumococcal conjugate vaccine (PCV) in comparison to the pneumococcal polysaccharide vaccine (PPV) to determine if a significantly better immunologic response to boosting can be elicited in patients previously vaccinated with PPV.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
275
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group 1pneumococcal conjugate vaccinePCV, 210 patients
Group 2pneumococcal polysaccharide vaccinePPV, 110 patients
Group 3pneumococcal polysaccharide vaccinePPV, HIV-negative, 25 patients
Primary Outcome Measures
NameTimeMethod
The measure of PPV and PCV efficacy will be assessed by the level of serotype-specific antibody levels, measured by ELISA.Day 180 after vaccination
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (6)

Tripler Army Medical Center

🇺🇸

Tripler AMC, Hawaii, United States

Naval Medical Center San Diego

🇺🇸

San Diego, California, United States

Walter Reed Army Medical Center

🇺🇸

Washington, District of Columbia, United States

San Antonio Military Medical Center

🇺🇸

Lackland AFB, Texas, United States

Naval Medical Center Portsmouth

🇺🇸

Portsmouth, Virginia, United States

National Naval Medical Center

🇺🇸

Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath